
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
A gut reaction : Treating chronic abdominal pain When the pill isn't right : Understanding alternative long-term contraception in adolescents Dermcase : Omphalitis in a newborn Puzzler : More than a Moro - The case of a twitching infant.






